Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Research and Innovation Action · Running

FORCE REPAIR smart and multiFunctional 3D printable prO-Regenerative biologiCal matrix modulating mEchanotRansduction as advancEd theraPy to treAt skIn chRonic wounds

Coordinator
Fundacion Cidetec, Spain
Runs
1 January 2023 to 31 December 2026
Status
Running
EU funding
€5.1m
Total cost
€5.1m
Partners
18 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101092243

What the project is doing

In the project's own words, from its summary on CORDIS.

Due to population lifestyle changes, i.e. obesity, diabetes and aging population, chronic wounds (CW) which fail to follow the typical healing process is a major medical socioeconomic challenge. Current wound management is clearly insufficient and advanced therapies failed in keeping their promise of reliable skin regeneration. The aim of FORCE REPAIR is to develop a smart and multifunctional wound dressing providing pro-regenerative environment and mechanical stability to treat CW.

Thus, FORCE REPAIR will combine state-of-the-art technologies in a biological scaffold tailored to patient’s needs: (1) Antibacterial and bioadhesive bioink with antibiotics and anti-inflammatory loaded nanocapsules, (2) Elastin like polypeptides promoting innervation and vascularization (3) Wharton Gel Complex preventing oxidative stress and boosting key extracellular matrix proteins. Also, the dressing activated by UV light will induce contractile force to help wound closure and activate skin regeneration.

A customized 3D bioprinter with a user-friendly 3D trajectory software will help to strategically placed the biological compounds to timely address and mitigate the degenerative process occurring in CW, i.e. infection, inflammation, tension forces to promote skin regeneration. The 3D printed dressing will be tested in relevant in vitro model with a human exudate library and testing relevant key healing steps (i.e. re-epithelization, angiogenesis, cell proliferation…).

Selected candidates will be tested in vivo on pig CW models and mice with bacterial infection. To ensure translation to clinical practice and reach patients, regulatory framework, HTA and a business model will be defined for a viable exploitation strategy that will decrease economic burden of wound care management and improve patients’ QoL. Finally, to ensure market acceptance health professional will guide the development of FORCE REPAIR to offer a dressing that treat efficiently CW and can be used by medical staff.

Topics

Who is involved

OrganisationCityCountryRole
Fundacion CidetecSan SebastianSpainCoordinator
Akribes Biomedical GmbHWienAustriaParticipant
Joanneum Research Forschungsgesellschaft MbhGrazAustriaParticipant
Betthera SroHradec KraloveCzechiaParticipant
Eurice European Research and Project Office GmbHSt IngbertGermanyParticipant
Cap Partner Aps, Ewma Secretariat Dfsg SecretariatFrederiksbergDenmarkParticipant
Asociacion Instituto De Investigacion Sanitaria BiogipuzkoaDonostia-San SebastianSpainThird party
Asphalion SLBarcelonaSpainParticipant
Fundacion Centro De Tecnologias De Interaccion Visual Y Comunicaciones VicomtechDonostia San SebastianSpainParticipant
Fundacion IdonialGijonSpainParticipant
Histocell SLDerio BizkaiaSpainParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Institut Polytechnique De BordeauxTalenceFranceThird party
Universite De BordeauxBordeauxFranceThird party
Research and Innovation Services Doo Za UslugeZagrebCroatiaThird party
Universita Degli Studi Del Piemonte Orientale Amedeo AvogadroVercelliItalyParticipant
Universita Degli Studi Di PaviaPaviaItalyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI